About
Philip Reilly is our Interim Chief Medical Officer and a Venture Partner at Third Rock Ventures. He is a highly respected clinical geneticist with an extensive track record in launching and building companies that seek to develop new therapies for rare genetic disorders. Dr. Reilly joined Third Rock in 2008 to focus on discovering, launching and building transformational companies dedicated to breakthrough treatments for rare diseases. Dr. Reilly is currently a Trustee of Cornell University and is on the Board of Overseers of Weill Cornell Medical College. Prior to joining Third Rock, he was the CEO and Chairman of Interleukin Genetics, and before that, he was the Executive Director of the Eunice Kennedy Shriver Center for Mental Retardation. He served twice (2000 and 2003) as president of the American Society of Law, Medicine and Ethics. He is a founding fellow of the American College of Medical Genetics. He has authored or co-authored more than 100 articles in scholarly journals as
Position in the VCSift Database
- • 24 investors at Third Rock Ventures are tracked.
- • 421 investors hold the Venture Partner role in VCSift. Philip Reilly is one of them.
- • 2,293 investors are based in Boston, Massachusetts, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Boston, US
Contact Information
Find more investors like Philip
Search Investors